Study on Preparation of New Purified Vero Cell Rabies Vaccine

Rabies is a 100% vaccine-preventable disease. A cheap, rabies vaccine for humans that could be used in mass vaccination campaigns would be a valuable weapon against rabies. Despite the existence of safe and effective vaccines, rabies disease still causes an estimated more human deaths a year in the endemic areas in Asia and Africa. Rabies virus is single stranded negative sense RNA from genus lyssavirus and _ family rhabdoviridae.

Download Full-text

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

Tropical Medicine and Infectious Disease ◽

10.3390/tropicalmed5010040 ◽

2020 ◽

Vol 5 (1) ◽

pp. 40 ◽

Cited By ~ 1

Author(s):

Thomas Moulenat ◽

Céline Petit ◽

Valérie Bosch Castells ◽

Guy Houillon

Keyword(s):

Systematic Review ◽

Vero Cell ◽

Rabies Virus ◽

Neutralizing Antibodies ◽

Rabies Vaccine ◽

Post Exposure Prophylaxis ◽

Post Exposure ◽

Exposure Prophylaxis ◽

Rabies Prevention ◽

Rabies Vaccination

The purified Vero cell rabies vaccine (PVRV; Verorab®, Sanofi Pasteur) has been used in rabies prevention since 1985. Evolving rabies vaccination trends, including shorter intradermal (ID) regimens with reduced volume, along with WHO recommendation for ID administration has driven recent ID PVRV regimen assessments. Thus, a consolidated review comparing immunogenicity of PVRV ID regimens during pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) is timely and beneficial in identifying gaps in current research. A search of seven databases for studies published from 1985 to November 2019 identified 35 studies. PrEP was assessed in 10 studies (n = 926) with 1–3-site, 1–3-visit regimens of up to 3-months duration. Seroconversion (rabies virus neutralizing antibodies [RVNA] ≥ 0.5 IU/mL) rates of 90–100% were reported within weeks, irrespective of regimen, with robust booster responses at 1 year (100% seroconversion rates by day 14 post-booster). However, data are lacking for the current WHO-recommended, 2-site, 1-week ID PrEP regimen. PEP was assessed in 25 studies (n = 2136) across regimens of 1-week to 90-day duration. All ID PEP regimens assessed induced ≥ 99% seroconversion rates (except in HIV participants) by day 14–28. This review confirms ID PVRV suitability for rabies prophylaxis and highlights the heterogeneity of use in the field.

Download Full-text

Serological profiling of rabies antibodies by enzyme-linked immunosorbent assay and its comparative analysis with rapid fluorescent focus inhibition test in mouse model

Veterinary World ◽

10.14202/vetworld.2019.126-130 ◽

2019 ◽

Vol 12 (1) ◽

pp. 126-130 ◽

Cited By ~ 1

Author(s):

Ashis Debnath ◽

Dinesh C. Pathak ◽

Narayan Ramamurthy ◽

Gulam Mohd ◽

A. B. Pandey ◽

...

Keyword(s):

Vero Cell ◽

Rabies Virus ◽

Immunosorbent Assay ◽

Disease Transmission ◽

Regression Line ◽

Rabies Vaccine ◽

Inhibition Test ◽

Enzyme Linked Immunosorbent Assay ◽

Mice Model ◽

Fluorescent Focus

Aim: In this study, we have used enzyme-linked immunosorbent assay (ELISA) as an alternative test to replace the cumbersome rapid fluorescent focus inhibition test (RFFIT) to ascertain the immune status of immunized mice against rabies virus. Materials and Methods: Rabies is a devastating disease worldwide caused by rabies virus. Proper usage of pre- or post-exposure rabies vaccine can prevent the disease transmission. In this study, mice were immunized with Vero cell-adapted inactivated rabies vaccine. RFFIT was used as a test to determine the serum neutralizing titers in infected/vaccinated mice. Seroprofiling of mice sera was done in vitro by ELISA. Results: Twenty-one days post-immunization, both ELISA and RFFIT assays indicated similar antibody levels in mice sera that were immunized with Vero cell-adapted inactivated rabies vaccine. Both the tests were correlated, and the linearity was verified by the regression line (R2=0.979). Conclusion: In this study, we profiled the serological status of Vero cell-adapted inactivated rabies vaccine through ELISA in mice model that correlated well with the OIE gold standard test RFFIT.

Download Full-text

TOTAL VACCINE-PREVENTABLE DISEASE INCIDENCE (VPDI) BY THE TEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV10) IN THE FINNISH NATIONAL VACCINATION PROGRAMME (NVP) IN CHILDREN

10.26226/morressier.58fa1765d462b80290b50ac0 ◽

2017 ◽

Author(s):

Arto Palmu

Keyword(s):

Conjugate Vaccine ◽

Vaccination Programme ◽

Pneumococcal Conjugate Vaccine ◽

Disease Incidence ◽

Vaccine Preventable Disease ◽

Preventable Disease ◽

National Vaccination Programme

Download Full-text

Faculty Opinions recommendation of Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717968517.793468253 ◽

2012 ◽

Author(s):

Mark Doherty

Keyword(s):

Vaccine Preventable Disease ◽

Preventable Disease

Download Full-text

Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries

Vaccine ◽

10.1016/j.vaccine.2021.01.066 ◽

2021 ◽

Author(s):

Molly Sauer ◽

Prarthana Vasudevan ◽

Ankita Meghani ◽

Karuna Luthra ◽

Cristina Garcia ◽

...

Keyword(s):

Vaccine Preventable Disease ◽

Middle Income ◽

Preventable Disease ◽

Middle Income Countries ◽

Situational Assessment ◽

Low And Middle Income

Download Full-text

MoRoNet a network to strengthen the quality of measles and rubella surveillance in Italy

European Journal of Public Health ◽

10.1093/eurpub/ckaa166.1336 ◽

2020 ◽

Vol 30 (Supplement_5) ◽

Author(s):

F Magurano ◽

M Baggieri ◽

P Bucci ◽

E D'Ugo ◽

M Sabbatucci ◽

...

Keyword(s):

Disease Surveillance ◽

Specific Work ◽

Vaccine Preventable Disease ◽

Work Plan ◽

Preventable Disease ◽

National Reference ◽

Disease Elimination ◽

National Networks ◽

Country Specific

Abstract Background Measles is a vaccine-preventable infectious disease and it remains one of the leading causes of infant mortality globally. The World Health Organization (WHO) has adopted the goal of eliminating measles and rubella. Detection and control of communicable diseases would not be possible without accurate laboratory results regarding when and where a particular disease circulates. Methods WHO/Europe therefore works with all Member States to steadily improve the quality of the laboratory data in order to determine the Region's progress towards measles and rubella elimination. For this purpose coordinates the European Measles and Rubella Laboratory Network (MR LabNet). National labs in this network undergoes regular external quality assessment through an annual accreditation programme. Results In Italy, a Sub-national Reference Laboratories Network for measles and rubella (MoRoNET) has been developed since March 2017 and currently includes 15 laboratories. MoRoNet was developed following the indications of the MR LabNet. It is accreditate, coordinated and supervised by the National Reference Laboratory. Conclusions Strengthening the role of national laboratories in overseeing the performance of subnational laboratories has become a critical need in order to properly monitor the Region's measles and rubella elimination efforts. MoRoNet permits to Italy to develop a country-specific work plan for establishing national networks and oversight mechanism, including preliminary monitoring and evaluation indicators compliant with MR LabNet standards. This is very significant not only to optimize the participation in national and regional processes to verify disease elimination, but also to strengthen the quality of vaccine-preventable disease surveillance. MoRoNet Group: A Amendola; F Baldanti; MR Capobianchi; M Chironna; MG Cusi; P D'Agaro; P Lanzafame; T Lazzarotto; K Marinelli; A Orsi; E Pagani; G Palù; F Pittaluga, A Sacchi; F Tramuto. Key messages MoRoNet has permitted to Italy to develop a country-specific work plan for establishing national networks and oversight mechanism, compliant with WHO MR LabNet standards. MoRoNet network has permitted to optimize the participation in processes to verify disease elimination, but also to strengthen the quality of vaccine-preventable disease surveillance.

Download Full-text

A New Method for Estimating the Coverage of Mass Vaccination Campaigns Against Poliomyelitis From Surveillance Data

American Journal of Epidemiology ◽

10.1093/aje/kwv199 ◽

2015 ◽

Vol 182 (11) ◽

pp. 961-970 ◽

Cited By ~ 4

Author(s):

K. M. O'Reilly ◽

A. Cori ◽

E. Durry ◽

M. Z. Wadood ◽

A. Bosan ◽

...

Keyword(s):

Mass Vaccination ◽

Surveillance Data ◽

New Method ◽

Vaccination Campaigns

Download Full-text

From epidemiology to public health decision making: analysis on IMD & vaccination strategy in Italy

European Journal of Public Health ◽

10.1093/eurpub/ckaa166.1451 ◽

2020 ◽

Vol 30 (Supplement_5) ◽

Author(s):

S Igidbashian ◽

F Caracci ◽

P Bonanni ◽

P Castiglia ◽

M Conversano ◽

...

Keyword(s):

Public Health ◽

Decision Making ◽

Adult Population ◽

Vaccination Strategy ◽

Healthcare Services ◽

Steady Increase ◽

Vaccine Preventable Disease ◽

Preventable Disease ◽

Italian Regions ◽

Age Range

Abstract Introduction Invasive Meningococcal Disease (IMD) is one of the most severe vaccine-preventable disease, with high fatality rate and severe sequelae in up to 20% of survivors. MenB, MenC and MenACWY vaccines are available in Italy, but recommendations vary among Italian regions in terms of type of vaccines and targeted age groups. The aim of the study is to describe epidemiology of IMDs in order to provide the best vaccination strategy. Methods IMDs surveillance data in the period 2011-2017 from the Italian National Health Institute were explored. Excel was used to present trend analysis, stratifying by age and serogroups. Results In Italy, during the period 2011-2017, IMDs overall incidence increased from 0.25 cases/100,000 inhabitants in 2011 to 0.33 in 2017. Most cases after 2013 were caused by non-B serogroups (52%, 52%, 66%, 64%, 59% from 2013 to 2017). Although incidence is highest in 1 years old children, the number of cases is highest in the age range 25-64. The number of cases in this age-range had a steady increase after 2013 (36 cases in 2011, 79 in 2017), with serogroups C, W and Y present in more than 65% of cases in 25+ age ranges after 2012. Conclusions IMD is a rare but severe vaccine-preventable disease. The key role of public health is to monitor disease serogroups, trends and outbreaks and strengthen methodological evidence-based tools for decision-making processes, public health policies, planning of healthcare services and intervention measures, including immunization. The increase in incidence shown in the period 2011-2017 in Italy, although probably due to better surveillance, highlighted the high circulation also of non-B serogroups and the importance of the disease in the adult population. Based on our analysis we believe that anti-meningococcal vaccination plan in Italy should include the highest number of preventable serogroups and be aimed to the whole population through a multicohort strategy, including boosters in children and in adults. Key messages Anti-meningococcal vaccination plan in Italy should include all the preventable serogroups and be aimed to the whole population with a multicohort strategy including boosters in children and in adults. The increase in incidence of IMD in the period 2011-2017 in Italy highlighted the high circulation also of non-B serogroups and the importance of the disease in the adult population.

Download Full-text